157 related articles for article (PubMed ID: 15892169)
1. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004.
Cicero TJ; Inciardi JA; Adams EH; Geller A; Senay EC; Woody GE; Muñoz A
Pharmacoepidemiol Drug Saf; 2005 Dec; 14(12):851-9. PubMed ID: 15892169
[TBL] [Abstract][Full Text] [Related]
2. The Diversion of Ultram, Ultracet, and generic tramadol HCL.
Inciardi JA; Cicero TJ; Munoz A; Adams EH; Geller A; Senay EC; Woody GE
J Addict Dis; 2006; 25(2):53-8. PubMed ID: 16785220
[TBL] [Abstract][Full Text] [Related]
3. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the abuse of tapentadol immediate release: the first 24 months.
Dart RC; Cicero TJ; Surratt HL; Rosenblum A; Bartelson BB; Adams EH
J Opioid Manag; 2012; 8(6):395-402. PubMed ID: 23264317
[TBL] [Abstract][Full Text] [Related]
5. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
Cicero TJ; Inciardi JA; Muñoz A
J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
[TBL] [Abstract][Full Text] [Related]
6. Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States.
Cicero TJ; Inciardi JA; Surratt H
Drug Alcohol Depend; 2007 Dec; 91(2-3):115-20. PubMed ID: 17590285
[TBL] [Abstract][Full Text] [Related]
7. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.
Bailey JE; Barton PL; Lezotte D; Lowenstein SR; Dart RC
Drug Alcohol Depend; 2006 Sep; 84(2):182-7. PubMed ID: 16510252
[TBL] [Abstract][Full Text] [Related]
8. Detecting signals of opioid analgesic abuse: application of a spatial mixed effect poisson regression model using data from a network of poison control centers.
Smith MY; Irish W; Wang J; Haddox JD; Dart RC
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1050-9. PubMed ID: 18803336
[TBL] [Abstract][Full Text] [Related]
9. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States.
Cicero TJ; Adams EH; Geller A; Inciardi JA; Muñoz A; Schnoll SH; Senay EC; Woody GE
Drug Alcohol Depend; 1999 Nov; 57(1):7-22. PubMed ID: 10617309
[TBL] [Abstract][Full Text] [Related]
10. Monitoring risk: post marketing surveillance and signal detection.
Dart RC
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S26-32. PubMed ID: 19748743
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain.
Adams EH; Breiner S; Cicero TJ; Geller A; Inciardi JA; Schnoll SH; Senay EC; Woody GE
J Pain Symptom Manage; 2006 May; 31(5):465-76. PubMed ID: 16716877
[TBL] [Abstract][Full Text] [Related]
12. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.
Cicero TJ; Surratt H; Inciardi JA; Munoz A
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):827-40. PubMed ID: 17636553
[TBL] [Abstract][Full Text] [Related]
13. FDA approvals of generic drugs: impact on the diversion of opioid analgesics with a potential for abuse.
Inciardi JA; Surratt HL; Stivers Y; Cicero TJ
J Opioid Manag; 2009; 5(2):81-7. PubMed ID: 19507804
[TBL] [Abstract][Full Text] [Related]
14. Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur.
Senay EC; Adams EH; Geller A; Inciardi JA; Muñoz A; Schnoll SH; Woody GE; Cicero TJ
Drug Alcohol Depend; 2003 Apr; 69(3):233-41. PubMed ID: 12633909
[TBL] [Abstract][Full Text] [Related]
15. Trends in opioid analgesic abuse and mortality in the United States.
Dart RC; Surratt HL; Cicero TJ; Parrino MW; Severtson SG; Bucher-Bartelson B; Green JL
N Engl J Med; 2015 Jan; 372(3):241-8. PubMed ID: 25587948
[TBL] [Abstract][Full Text] [Related]
16. Source of drugs for prescription opioid analgesic abusers: a role for the Internet?
Cicero TJ; Shores CN; Paradis AG; Ellis MS
Pain Med; 2008 Sep; 9(6):718-23. PubMed ID: 18816331
[TBL] [Abstract][Full Text] [Related]
17. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
[TBL] [Abstract][Full Text] [Related]
18. Major increases in opioid analgesic abuse in the United States: concerns and strategies.
Compton WM; Volkow ND
Drug Alcohol Depend; 2006 Feb; 81(2):103-7. PubMed ID: 16023304
[TBL] [Abstract][Full Text] [Related]
19. An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride).
Woody GE; Senay EC; Geller A; Adams EH; Inciardi JA; Schnoll S; Muñoz A; Cicero TJ
Drug Alcohol Depend; 2003 Nov; 72(2):163-8. PubMed ID: 14636971
[TBL] [Abstract][Full Text] [Related]
20. Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007.
Schneider MF; Bailey JE; Cicero TJ; Dart RC; Inciardi JA; Parrino M; Muñoz A
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):778-90. PubMed ID: 19536784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
